276 related articles for article (PubMed ID: 27226433)
1. Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy.
Herling CD; Klaumünzer M; Rocha CK; Altmüller J; Thiele H; Bahlo J; Kluth S; Crispatzu G; Herling M; Schiller J; Engelke A; Tausch E; Döhner H; Fischer K; Goede V; Nürnberg P; Reinhardt HC; Stilgenbauer S; Hallek M; Kreuzer KA
Blood; 2016 Jul; 128(3):395-404. PubMed ID: 27226433
[TBL] [Abstract][Full Text] [Related]
2. Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO-CLLEAR Study by the Czech CLL Study Group.
Panovská A; Němcová L; Nekvindová L; Špaček M; Šimkovič M; Papajík T; Brejcha M; Lysák D; Zuchnická J; Novák J; Starostka D; Poul H; Vrbacký F; Vodárek P; Urbanová R; Plevová K; Pospíšilová Š; Mašlejová S; Brychtová Y; Koriťáková E; Smolej L; Doubek M
Hematol Oncol; 2020 Oct; 38(4):509-516. PubMed ID: 32400885
[TBL] [Abstract][Full Text] [Related]
3. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
Spunarova M; Tom N; Pavlova S; Mraz M; Brychtova Y; Doubek M; Panovska A; Skuhrova Francova H; Brzobohata A; Pospisilova S; Mayer J; Trbusek M
Leuk Res; 2019 Jun; 81():75-81. PubMed ID: 31054420
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.
Tausch E; Schneider C; Robrecht S; Zhang C; Dolnik A; Bloehdorn J; Bahlo J; Al-Sawaf O; Ritgen M; Fink AM; Eichhorst B; Kreuzer KA; Tandon M; Humphrey K; Jiang Y; Schary W; Bullinger L; Mertens D; Lurà MP; Kneba M; Döhner H; Fischer K; Hallek M; Stilgenbauer S
Blood; 2020 Jun; 135(26):2402-2412. PubMed ID: 32206772
[TBL] [Abstract][Full Text] [Related]
5. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients.
Foà R; Del Giudice I; Cuneo A; Del Poeta G; Ciolli S; Di Raimondo F; Lauria F; Cencini E; Rigolin GM; Cortelezzi A; Nobile F; Callea V; Brugiatelli M; Massaia M; Molica S; Trentin L; Rizzi R; Specchia G; Di Serio F; Orsucci L; Ambrosetti A; Montillo M; Zinzani PL; Ferrara F; Morabito F; Mura MA; Soriani S; Peragine N; Tavolaro S; Bonina S; Marinelli M; De Propris MS; Starza ID; Piciocchi A; Alietti A; Runggaldier EJ; Gamba E; Mauro FR; Chiaretti S; Guarini A
Am J Hematol; 2014 May; 89(5):480-6. PubMed ID: 24415640
[TBL] [Abstract][Full Text] [Related]
6. The Impact of Chlorambucil and Valproic Acid on Cell Viability, Apoptosis and Expression of
Lipska K; Filip A; Gumieniczek A
Cells; 2021 May; 10(5):. PubMed ID: 34063233
[TBL] [Abstract][Full Text] [Related]
7. Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group.
Herishanu Y; Shaulov A; Fineman R; Bašić-Kinda S; Aviv A; Wasik-Szczepanek E; Jaksic O; Zdrenghea M; Greenbaum U; Mandac I; Simkovic M; Morawska M; Benjamini O; Spacek M; Nemets A; Bairey O; Trentin L; Ruchlemer R; Laurenti L; Stanca Ciocan O; Doubek M; Shvidel L; Dali N; Mirás F; De Meûter A; Dimou M; Mauro FR; Coscia M; Bumbea H; Szász R; Tadmor T; Gutwein O; Gentile M; Scarfò L; Tedeschi A; Sportoletti P; Gimeno Vázquez E; Marquet J; Assouline S; Papaioannou M; Braester A; Levato L; Gregor M; Rigolin GM; Loscertales J; Medina Perez A; Nijziel MR; Popov VM; Collado R; Slavutsky I; Itchaki G; Ringelstein S; Goldschmidt N; Perry C; Levi S; Polliack A; Ghia P
Am J Hematol; 2020 Jun; 95(6):604-611. PubMed ID: 32096887
[TBL] [Abstract][Full Text] [Related]
8. Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations.
Rigolin GM; Saccenti E; Bassi C; Lupini L; Quaglia FM; Cavallari M; Martinelli S; Formigaro L; Lista E; Bardi MA; Volta E; Tammiso E; Melandri A; Urso A; Cavazzini F; Negrini M; Cuneo A
J Hematol Oncol; 2016 Sep; 9(1):88. PubMed ID: 27633522
[TBL] [Abstract][Full Text] [Related]
9. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.
Le Bris Y; Struski S; Guièze R; Rouvellat C; Prade N; Troussard X; Tournilhac O; Béné MC; Delabesse E; Ysebaert L
Hematol Oncol; 2017 Dec; 35(4):664-670. PubMed ID: 27678008
[TBL] [Abstract][Full Text] [Related]
10. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY.
Mansouri L; Thorvaldsdottir B; Sutton LA; Karakatsoulis G; Meggendorfer M; Parker H; Nadeu F; Brieghel C; Laidou S; Moia R; Rossi D; Catherwood M; Kotaskova J; Delgado J; Rodríguez-Vicente AE; Benito R; Rigolin GM; Bonfiglio S; Scarfo L; Mattsson M; Davis Z; Gogia A; Rani L; Baliakas P; Foroughi-Asl H; Jylhä C; Skaftason A; Rapado I; Miras F; Martinez-Lopez J; de la Serna J; Rivas JMH; Thornton P; Larráyoz MJ; Calasanz MJ; Fésüs V; Mátrai Z; Bödör C; Smedby KE; Espinet B; Puiggros A; Gupta R; Bullinger L; Bosch F; Tazón-Vega B; Baran-Marszak F; Oscier D; Nguyen-Khac F; Zenz T; Terol MJ; Cuneo A; Hernández-Sánchez M; Pospisilova S; Mills K; Gaidano G; Niemann CU; Campo E; Strefford JC; Ghia P; Stamatopoulos K; Rosenquist R
Leukemia; 2023 Feb; 37(2):339-347. PubMed ID: 36566271
[TBL] [Abstract][Full Text] [Related]
11. NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment.
Chiaretti S; Marinelli M; Del Giudice I; Bonina S; Piciocchi A; Messina M; Vignetti M; Rossi D; Di Maio V; Mauro FR; Guarini A; Gaidano G; Foà R
Leuk Lymphoma; 2014 Dec; 55(12):2785-92. PubMed ID: 24597984
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1.
Tausch E; Beck P; Schlenk RF; Jebaraj BJ; Dolnik A; Yosifov DY; Hillmen P; Offner F; Janssens A; Babu GK; Grosicki S; Mayer J; Panagiotidis P; McKeown A; Gupta IV; Skorupa A; Pallaud C; Bullinger L; Mertens D; Döhner H; Stilgenbauer S
Haematologica; 2020 Oct; 105(10):2440-2447. PubMed ID: 33054084
[TBL] [Abstract][Full Text] [Related]
13. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
Goede V; Fischer K; Busch R; Engelke A; Eichhorst B; Wendtner CM; Chagorova T; de la Serna J; Dilhuydy MS; Illmer T; Opat S; Owen CJ; Samoylova O; Kreuzer KA; Stilgenbauer S; Döhner H; Langerak AW; Ritgen M; Kneba M; Asikanius E; Humphrey K; Wenger M; Hallek M
N Engl J Med; 2014 Mar; 370(12):1101-10. PubMed ID: 24401022
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.
Nadeu F; Delgado J; Royo C; Baumann T; Stankovic T; Pinyol M; Jares P; Navarro A; Martín-García D; Beà S; Salaverria I; Oldreive C; Aymerich M; Suárez-Cisneros H; Rozman M; Villamor N; Colomer D; López-Guillermo A; González M; Alcoceba M; Terol MJ; Colado E; Puente XS; López-Otín C; Enjuanes A; Campo E
Blood; 2016 Apr; 127(17):2122-30. PubMed ID: 26837699
[TBL] [Abstract][Full Text] [Related]
15. High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.
Fürstenau M; Thus YJ; Robrecht S; Mellink CHM; van der Kevie-Kersemaekers AM; Dubois J; von Tresckow J; Patz M; Gregor M; Thornton P; Staber PB; Tadmor T; Levin MD; da Cunha-Bang C; Schneider C; Poulsen CB; Illmer T; Schöttker B; Janssens A; Christiansen I; Nösslinger T; Baumann M; Hebart H; Gaska T; Regelink JC; Dompeling EC; Lindström V; Juliusson G; Widmer A; Goede J; Goldschmidt N; Simon F; De Silva N; Fink AM; Fischer K; Wendtner CM; Ritgen M; Brüggemann M; Tausch E; Spaargaren M; Eldering E; Stilgenbauer S; Niemann CU; Hallek M; Eichhorst B; Kreuzer KA; Kater AP
Blood; 2023 Aug; 142(5):446-459. PubMed ID: 37172204
[TBL] [Abstract][Full Text] [Related]
16. Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.
Xia Y; Fan L; Wang L; Gale RP; Wang M; Tian T; Wu W; Yu L; Chen YY; Xu W; Li JY
Oncotarget; 2015 Mar; 6(7):5426-34. PubMed ID: 25605254
[TBL] [Abstract][Full Text] [Related]
17. A Systematic Review and Network Meta-Analysis to Evaluate the Comparative Efficacy of Interventions for Unfit Patients with Chronic Lymphocytic Leukemia.
Städler N; Shang A; Bosch F; Briggs A; Goede V; Berthier A; Renaudin C; Leblond V
Adv Ther; 2016 Oct; 33(10):1814-1830. PubMed ID: 27535291
[TBL] [Abstract][Full Text] [Related]
18. Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments.
Hu B; Patel KP; Chen HC; Wang X; Wang F; Luthra R; Routbort MJ; Kanagal-Shamanna R; Medeiros LJ; Yin CC; Zuo Z; Ok CY; Loghavi S; Tang G; Tambaro FP; Thompson P; Burger J; Jain N; Ferrajoli A; Bose P; Estrov Z; Keating MJ; Wierda WG
Br J Haematol; 2019 Jun; 185(5):852-864. PubMed ID: 30924136
[TBL] [Abstract][Full Text] [Related]
19. POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia.
Ramsay AJ; Quesada V; Foronda M; Conde L; Martínez-Trillos A; Villamor N; Rodríguez D; Kwarciak A; Garabaya C; Gallardo M; López-Guerra M; López-Guillermo A; Puente XS; Blasco MA; Campo E; López-Otín C
Nat Genet; 2013 May; 45(5):526-30. PubMed ID: 23502782
[TBL] [Abstract][Full Text] [Related]
20. Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM).
González-Rincón J; Garcia-Vela JA; Gómez S; Fernández-Cuevas B; Nova-Gurumeta S; Pérez-Sanz N; Alcoceba M; González M; Anguita E; López-Jiménez J; González-Barca E; Yáñez L; Pérez-Persona E; de la Serna J; Fernández-Zarzoso M; Deben G; Peñalver FJ; Fernández MC; de Oteyza JP; Andreu MÁ; Ruíz-Guinaldo MÁ; Paz-Arias R; García-Malo MD; Recasens V; Collado R; Córdoba R; Navarro-Matilla B; Sánchez-Beato M; García-Marco JA
PLoS One; 2021; 16(9):e0257353. PubMed ID: 34506616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
